Skip to content

InTake Care: Development and Validation of an Innovative, Personalized Digital Health Solution for Medication Adherence Support in Cardiovascular Prevention

InTake Care: Development and Validation of an Innovative, Personalized Digital Health Solution for Medication Adherence Support in Cardiovascular Prevention

Status
Recruiting
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT06229171
Acronym
InTakeCare
Enrollment
206
Registered
2024-01-29
Start date
2024-10-01
Completion date
2026-04-01
Last updated
2025-08-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Digital Health, Hypertension, Treatment Adherence and Compliance

Keywords

Personalized Medicine

Brief summary

Inadequate medication adherence (MA) in chronic conditions, including cardiovascular prevention, represents an important risk factor. The use of new IT technologies in this setting is supposed to be useful to improve patients' adherence, but currently available solutions have significant limitations, including lack of personalization and reliance on expensive ad hoc systems. This interdisciplinary project aims to verify the hypothesis that in patients on chronic antihypertensive treatment MA can be improved through the implementation of a novel digital health solution for MA monitoring and support, based on inexpensive and user-friendly, commercially available technology (voice assistant), connected with web interface for the physician. The intervention will be personalized based on the creation of Personas, intended as multidisciplinary-based representations of different user types. This approach will be tested in a randomized clinical trial.

Interventions

OTHERadherence support system based on a vocal assistant

Participants in the intervention group will receive a vocal assistant device and the instructions/support for the activation of the system at their homes. The device will remind the participant, at the times defined during set-up, which therapy should be taken and with what dosage. The participant will have 30 minutes from the first reminder to confirm vocally that the therapy has been taken, which will otherwise be considered as not having been taken. Participants in the control group will receive verbal advice from the physician about the need to follow the treatment recommendations and simple indications on possible solutions to maintain adherence, as by the usual practice of the Centre.

Sponsors

Istituti Clinici Scientifici Maugeri SpA
CollaboratorOTHER
Politecnico di Milano
CollaboratorOTHER
Istituto Auxologico Italiano
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
OTHER
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Adult (\>18 years old) patients * History of essential hypertension * Treatment with at least one antihypertensive drug for which dedicated plasma essay is available * wireless internet connection available at patients' home * stable clinical conditions * written informed consent

Exclusion criteria

* insufficient technological literacy to manage vocal assistant * dementia or significant psychiatric disorders * conditions significantly limiting vocal communication (deafness, significant speech disorders, poor knowledge of Italian language) * pregnancy or breastfeeding * active cancer (except basal cell skin carcinoma) * upper limb amputation

Design outcomes

Primary

MeasureTime frameDescription
Adherence (plasma essay - 3m)after 3 months of randomized interventionPercentage of adherent patients based on plasma essay at follow-up visit

Secondary

MeasureTime frameDescription
adherence (pill count - 3m)after 3 months of randomized interventionpercentage of adherent patients based on pill count adherence (AdhVA) at follow-up visit
adherence (voice assistant - 3m)after 3 months of randomized interventionpercentage of adherent patients based on voice assistant adherence (AdhVA) at follow-up visit
adherence (questionnaire - 3m)after 3 months of randomized interventionpercentage of adherent patients based on MARS-5I (Medication Adherence Report Scale-5 Italian version) at follow-up visit
Adherence (plasma essay - 5m)after 5 monthspercentage of adherent patients based on plasma essay at final visit
24h Systolic Blood Pressure (5m)after 5 months24-hour systolic blood pressure (ABPM) at final visit
adherence (voice assistant - 5m)after 5 monthspercentage of adherent patients based on voice assistant adherence (AdhVA) at final visit
adherence (questionnaire - 5m)after 5 monthspercentage of adherent patients based on MARS-5I at final visit
24h Systolic Blood Pressure (3m)after 3 months of randomized intervention24-hour systolic blood pressure (ABPM) at follow-up visit
adherence (pill count - 5m)after 5 monthspercentage of adherent patients based on pill count adherence (AdhVA) at final visit

Countries

Italy

Contacts

Primary ContactGrzegorz Bilo, MD, PhD
g.bilo@auxologico.it+390261911
Backup ContactLucia Zanotti, Bsc, PhD
l.zanotti@auxologico.it+390261911

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026